Evidence map›Paper›PMID 33922716›Full record

ArticleViruses2021

Accessible LAMP-Enabled Rapid Test (ALERT) for Detecting SARS-CoV-2.

Ali Bektaş, Michael F Covington, Guy Aidelberg, Anibal Arce, Tamara Matute, Isaac Núñez, Julia Walsh, David Boutboul, Constance Delaugerre, Ariel B Lindner and 2 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Rapid, Affordable, and Scalable SARS-CoV-2 Detection From Saliva.Journal of biomolecular techniques : JBT · 2021
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Ali BektaşOakland Genomics Center, 355 30th Street, Oakland, CA 94609, USA.
Michael F CovingtonOakland Genomics Center, 355 30th Street, Oakland, CA 94609, USA.
Guy AidelbergCenter for Research and Interdisciplinarity (CRI), Université de Paris, INSERM U1284, F-75006 Paris, France.
Anibal ArceInstitute for Biological and Medical Engineering, Schools of Engineering, Biology and Medicine, Pontificia Universidad Católica de Chile, Santiago 7820244, Chile.
Tamara MatuteInstitute for Biological and Medical Engineering, Schools of Engineering, Biology and Medicine, Pontificia Universidad Católica de Chile, Santiago 7820244, Chile.ORCID 0000-0002-0486-985X
Isaac NúñezInstitute for Biological and Medical Engineering, Schools of Engineering, Biology and Medicine, Pontificia Universidad Católica de Chile, Santiago 7820244, Chile.ORCID 0000-0002-4439-3745
Julia WalshSchool of Public Health, University of California Berkeley, Berkeley, CA 94720, USA.
David BoutboulClinical Immunology Department, U976 HIPI, Hôpital Saint Louis, Université de Paris, F-75006 Paris, France.ORCID 0000-0002-5006-8279
Constance DelaugerreClinical Immunology Department, U976 HIPI, Hôpital Saint Louis, Université de Paris, F-75006 Paris, France.
Ariel B LindnerCenter for Research and Interdisciplinarity (CRI), Université de Paris, INSERM U1284, F-75006 Paris, France.
Fernán FedericiInstitute for Biological and Medical Engineering, Schools of Engineering, Biology and Medicine, Pontificia Universidad Católica de Chile, Santiago 7820244, Chile.
Anitha D JayaprakashOakland Genomics Center, 355 30th Street, Oakland, CA 94609, USA.
Pontificia Universidad Católica de Chile · CLInserm · FRUniversité Paris Cité · FRBerkeley Public Health Division · US

Funding

ANID CONCYTEC covbio0012ANID - Millennium Science Initiative Program ICN17_022Just One Giant Lab (JOGL) N/AUC Berkeley Center for Emerging and Neglected Diseases COVID-CATALYST Grant
6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has highlighted bottlenecks in large-scale, frequent testing of populations for infections. Polymerase chain reaction (PCR)-based diagnostic tests are expensive, reliant on centralized labs, can take days to deliver results, and are prone to backlogs and supply shortages. Antigen tests that bind and detect the surface proteins of a virus are rapid and scalable but suffer from high false negative rates. To address this problem, an inexpensive, simple, and robust 60-minute do-it-yourself (DIY) workflow to detect viral RNA from nasal swabs or saliva with high sensitivity (0.1 to 2 viral particles/μL) and specificity (>97% true negative rate) utilizing reverse transcription loop-mediated isothermal amplification (RT-LAMP) was developed. ALERT (Accessible LAMP-Enabled Rapid Test) incorporates the following features: (1) increased shelf-life and ambient temperature storage, compared to liquid reaction mixes, by using wax layers to isolate enzymes from other reagents; (2) improved specificity compared to other LAMP end-point reporting methods, by using sequence-specific QUASR (quenching of unincorporated amplification signal reporters); (3) increased sensitivity, compared to methods without purification through use of a magnetic wand to enable pipette-free concentration of sample RNA and cell debris removal; (4) quality control with a nasopharyngeal-specific mRNA target; and (5) co-detection of other respiratory viruses, such as influenza B, by multiplexing QUASR-modified RT-LAMP primer sets. The flexible nature of the ALERT workflow allows easy, at-home and point-of-care testing for individuals and higher-throughput processing for labs and hospitals. With minimal effort, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific primer sets can be swapped out for other targets to repurpose ALERT to detect other viruses, microorganisms, or nucleic acid-based markers.

Indexed as

Clinical Laboratory TechniquesCOVID-19COVID-19 TestingHumansMaleMolecular Diagnostic TechniquesNasopharynxNucleic Acid Amplification TechniquesPoint-of-Care TestingRNA, ViralSARS-CoV-2Sensitivity and SpecificityRNA, Viralbiodetectionpoint-of-careRT-LAMPSARS-CoV-2

Identifiers

PMID33922716
PMCPMC8146324
OpenAlexW3157367227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.